US Patent

US10857102 — Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate

Formulation · Assigned to Janssen Sciences Ireland ULC · Expires 2033-01-14 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects multilayer tablets containing rilpivirine hydrochloride, emtricitabine, and tenofovir disoproxil fumarate for treating HIV.

USPTO Abstract

The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.

Drugs covered by this patent

Patent Metadata

Patent number
US10857102
Jurisdiction
US
Classification
Formulation
Expires
2033-01-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.